Fukuda Izumi, Hizuka Naomi, Itoh Emina, Yasumoto Kumiko, Ishikawa Yukiko, Murakami Yuko, Sata Akira, Takano Kazue
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Endocr J. 2002 Jun;49(3):379-86. doi: 10.1507/endocrj.49.379.
In serum, insulin-like growth factors (IGFs) are primarily present as a approximately 150 kDa ternary protein complex, which consists of IGFs, IGF binding protein-3 (IGFBP-3), and acid-labile subunit (ALS). Like IGF-I and IGFBP-3, serum levels of ALS depend on growth hormone (GH). To date, the diagnostic relevance of ALS in adult GH deficiency (GHD) has remained uncertain. To clarify the clinical utility of ALS measurement in adults, we measured serum ALS levels in patients with adult GHD or acromegaly. We also measured the levels of serum IGF-I and IGFBP-3 in these patients to compare the utility of ALS with IGF-I and IGFBP-3 as a marker of GH secretion. Serum ALS was measured by radioimmunoassay (RIA) kit, and serum IGF-I and IGFBP-3 were measured by immunoradiometric assay (IRMA) kits in 56 patients with adult GHD (adult-onset (AO)/child-onset (CO), 13/43) and 43 patients with acromegaly. Serum ALS levels were less than 5th percentile in 40 of 56 (71%) patients with adult GHD (32/43 (74%) for CO and 8/13 (62%) for AO), and more than 95th percentile in 38 of 43 (88%) patients with acromegaly, respectively. Serum IGF-I levels were less than -1.96 SD in 43 of 56 (77%) patients with adult GHD (35/43 (81%) for CO and 8/13 (62%) for AO) and more than +1.96 SD in 42 of 43 (98%) patients with acromegaly, respectively. Serum IGFBP-3 levels were less than -1.96 SD in 51 of 56 (91%) patients with adult GHD (42/43 (98%) for CO and 9/13 (69%) for AO) and more than +1.96 SD in 31 of 43 (72%) patients with acromegaly, respectively. These data suggested that measurement of ALS offers no advantage over measurements of serum IGF-I and IGFBP-3. Furthermore, our results indicate that serum IGFBP-3 is the most suitable marker of GH secretion for adult GHD, especially CO, while IGF-I may be the most useful in acromegaly.
在血清中,胰岛素样生长因子(IGFs)主要以大约150 kDa的三元蛋白复合物形式存在,该复合物由IGFs、胰岛素样生长因子结合蛋白-3(IGFBP-3)和酸不稳定亚基(ALS)组成。与IGF-I和IGFBP-3一样,ALS的血清水平取决于生长激素(GH)。迄今为止,ALS在成人生长激素缺乏症(GHD)中的诊断相关性仍不明确。为了阐明ALS检测在成人中的临床应用价值,我们检测了成人GHD或肢端肥大症患者的血清ALS水平。我们还检测了这些患者的血清IGF-I和IGFBP-3水平,以比较ALS与IGF-I和IGFBP-3作为GH分泌标志物 utility的情况。采用放射免疫分析(RIA)试剂盒检测56例成人GHD患者(成人起病(AO)/儿童起病(CO),13/43)和43例肢端肥大症患者的血清ALS水平,采用免疫放射分析(IRMA)试剂盒检测血清IGF-I和IGFBP-3水平。56例成人GHD患者中有40例(71%)血清ALS水平低于第5百分位数(CO组32/43(74%),AO组8/13(62%)),43例肢端肥大症患者中有占38例(88%)血清ALS水平高于第95百分位数。56例成人GHD患者中有43例(77%)血清IGF-I水平低于-1.96 SD(CO组35/43(81%),AO组8/13(62%)),43例肢端肥大症患者中有42例(98%)血清IGF-I水平高于+1.96 SD。56例成人GHD患者中有51例(91%)血清IGFBP-3水平低于-1.96 SD(CO组42/43(98%),AO组9/13(69%)),43例肢端肥大症患者中有31例(72%)血清IGFBP-3水平高于+1.96 SD。这些数据表明,检测ALS并不比检测血清IGF-I和IGFBP-3更具优势。此外,我们的结果表明,血清IGFBP-3是成人GHD尤其是CO型最适合的GH分泌标志物,而IGF-I可能在肢端肥大症中最有用。